At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 99 enrolled
Drug / intervention
Ixekizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of 2 Ixekizumab Test Formulations Compared to the Commercial Formulation in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Ixekizumab for Healthy. Completed, enrolled 99 participants across 1 site.
Detailed Summary
The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1 and Test 2) have not been approved. This study will compare how much of each of the three formulations get into the blood stream. Information about any side effects that may occur will also be collected.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedFeb 2019
Primary CompletionJun 2019
TodayJul 2026
First PostedFeb 20, 2019
Enrollment StartJan 29, 2019
Primary CompletionJun 7, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.4 years ago
Interventions
Ixekizumabbiological
Administered SC